Latest news with #DavidRisinger
Yahoo
6 days ago
- Business
- Yahoo
Why Roivant Sciences Stock Bounced Back on Tuesday
Key Points A day after it published its latest set of quarterly earnings, an analyst bumped his price target higher. He also maintained his equivalent of a buy recommendation. 10 stocks we like better than Roivant Sciences › Monday's hangover turned into Tuesday's party for healthcare stock Roivant Sciences (NASDAQ: ROIV). On the back of a modest but meaningful analyst price target hike, investors bid the stock up by nearly 4% following a post-earnings slide the day before. With the Tuesday rise, Roivant handily beat the benchmark S&P 500 index, which bumped 1.1% higher. Boosting the biotech Tuesday's raiser was Leerink Partners prognosticator David Risinger. Well before market open, he added $1 to his Roivant price target for a new level of $18 per share. In doing so, he maintained his recommendation of outperform (read: buy) on the company's stock. According to reports, Risinger's adjustment is based on a change in his forecast for the biotech company's share count. The analyst based this on management's statements about its share repurchase program, which is expected to shave the tally for shares outstanding. As for Roivant's operations, the pundit waxed bullish on the eventual outcome of the company's phase 3 clinical trial of brepocitinib in the treatment of dermatomyositis, a rare inflammatory disease that can affect the muscles and the skin. He's anticipating a readout of the trial to be published in the second half of this year. A first quarter to forget Risinger's continued bullishness on Roivant was a morale-booster for the market, which had traded out of the company's shares after Monday's fiscal first quarter of 2026 earnings release. The company reported significantly lower revenue compared to the same period of 2025, and it flipped to a net loss on the bottom line. Should you buy stock in Roivant Sciences right now? Before you buy stock in Roivant Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Roivant Sciences wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy. Why Roivant Sciences Stock Bounced Back on Tuesday was originally published by The Motley Fool Sign in to access your portfolio
CNBC
07-08-2025
- Business
- CNBC
Leerink's Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill results
David Risinger, Leerink Partners senior research analyst, joins 'Power Lunch' to discuss how competitive Eli Lilly's business is, what to expect by the end of the decade and much more.
Globe and Mail
16-07-2025
- Business
- Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report) and Alkermes (ALKS – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. AbbVie (ABBV) Leerink Partners analyst David Risinger maintained a Buy rating on AbbVie on July 10. The company's shares closed last Monday at $191.52. According to Risinger is a 5-star analyst with an average return of 9.1% and a 54.3% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Centessa Pharmaceuticals, and Vertex Pharmaceuticals. ;'> AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $212.00, implying a 10.6% upside from current levels. In a report issued on June 30, William Blair also maintained a Buy rating on the stock. Alkermes (ALKS) Leerink Partners analyst Marc Goodman maintained a Hold rating on Alkermes on July 11. The company's shares closed last Monday at $29.69. According to Goodman is a 4-star analyst with an average return of 4.5% and a 47.0% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, ACADIA Pharmaceuticals, and Avadel Pharmaceuticals. ;'> Alkermes has an analyst consensus of Moderate Buy, with a price target consensus of $40.00, representing a 32.5% upside. In a report issued on July 7, RBC Capital also maintained a Hold rating on the stock with a $40.00 price target.
Business Insider
21-06-2025
- Business
- Business Insider
Why Is OceanPal Stock (OP) Down 20% Today?
OceanPal (OP) stock was down on Friday after the ocean-going transportation services company revealed plans for a public offering. That preliminary prospectus included plans to sell 9,316,770 shares of OP stock for an assumed price of $1.61 each. The shares would come bundled with warrants, which will allow holders to exercise them for additional shares. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The expected offering price of $1.61 per share is well below OP stock's prior closing price of $2.20, explaining why shares have fallen today. Additionally, the increase in outstanding shares will dilute the stakes of current investors, which is another factor that weighed down OP stock on Friday. Shares of OP stock were down 20% as of Friday morning, following a 24.14% drop on Wednesday. Investors will note that markets were closed yesterday for Juneteenth. Is OceanPal Stock a Buy, Sell, or Hold? Turning to Wall Street, four-star Leerink Partners analyst David Risinger offers the only coverage of OceanPal. He has a Buy rating for the shares with no price target. Spark, TipRanks' AI analyst, rates OP stock a Neutral (46) with no price target. It cites 'significant financial challenges, including negative profitability and cash flow issues' as reasons for this rating.
Business Insider
19-06-2025
- Business
- Business Insider
Leerink Partners Keeps Their Buy Rating on Tenax Therapeutics (TENX)
Leerink Partners analyst David Risinger reiterated a Buy rating on Tenax Therapeutics (TENX – Research Report) yesterday. The company's shares closed yesterday at $5.67. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Risinger is a 5-star analyst with an average return of 8.7% and a 52.65% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Regeneron. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tenax Therapeutics with a $21.67 average price target.
